India Glycols Posts Strong Q3 Growth, Eyes Strategic Demerger

CHEMICALS
Whalesbook Logo
AuthorVihaan Mehta|Published at:
India Glycols Posts Strong Q3 Growth, Eyes Strategic Demerger
Overview

India Glycols Limited (IGL) posted a solid Q3 FY26 with standalone revenue up 5.25% YoY to ₹2,551 Cr and PAT surging 21.05% to ₹65 Cr. Nine-month figures also show robust growth. The company is proceeding with a demerger of its Bio Pharma and Spirits & Biofuel undertakings, setting April 1, 2026, as the appointed date, following stock exchange and NCLT approvals. This strategic move aims to unlock value and create focused entities.

India Glycols Limited (IGL) has announced robust financial results for the third quarter and nine months ended December 31, 2025.

📉 The Financial Deep Dive

Standalone Performance (Q3 FY26):

  • Revenue from operations: ₹2,551.06 Cr, a 5.25% increase year-on-year (YoY).
  • Profit After Tax (PAT): ₹65.07 Cr, marking a significant 21.05% YoY growth.
  • An exceptional item of ₹0.83 Cr, related to employee benefits under new Labour Codes, was recognized.

Consolidated Performance (Q3 FY26):

  • Revenue from operations: ₹2,551.10 Cr, up 5.24% YoY.
  • PAT: ₹67.57 Cr, an 18.9% YoY increase.

The nine-month period also demonstrated healthy growth, with consolidated revenue at ₹7,466.62 Cr (YoY 8.99%) and PAT at ₹205.88 Cr (YoY 23.35%).

🚀 Strategic Analysis & Impact

The company is actively pursuing a Composite Scheme of Arrangement, focusing on demerging its Bio Pharma undertaking into Ennature Bio Pharma Limited and the Spirits & Biofuel Undertaking into IGL Spirits Limited. The Board has dropped the earlier proposal for amalgamation with Kashipur Holdings Limited. The appointed date for this crucial demerger is set for April 1, 2026. Significant progress has been made, with the company receiving 'No Objection/Observation Letters' from stock exchanges and the National Company Law Tribunal (NCLT) allowing its First Motion Application on January 15, 2026.

Additionally, IGL completed a stock split in FY25, subdividing equity shares from ₹10 to ₹5 face value, and a preferential allotment in November 2025, raising approximately ₹467 Cr by issuing shares at ₹915 each, thereby bolstering its paid-up share capital.

🚩 Risks & Outlook

Investors will closely monitor the execution and timeline of the demerger process, ensuring timely regulatory approvals and smooth transition for the newly formed entities. Market reception to the strategic restructuring and the performance of the demerged businesses will be key.

Impact: 7/10 - The robust quarterly performance coupled with a significant strategic demerger plan to unlock business potential positions the company positively, though execution risk remains.

Terms Explained:

  • PAT (Profit After Tax): The profit remaining after all expenses and taxes have been deducted from the total revenue.
  • YoY (Year-on-Year): Comparing performance from one period to the same period in the previous year.
  • Demerger: A corporate restructuring where a company splits into two or more independent companies.
  • Appointed Date: The date from which the demerger is legally effective, often used for accounting purposes.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.